Drugs / anti-FLT3 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05023707 | Dec 2021 → Jun 2023 | acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-FLT3 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05023707 ↗ |
| Modality | Cell therapy | “anti-FLT3 chimeric antigen receptor engineered T cell immunotherapy (CART)” NCT05023707 ↗ |
| Route | Intravenous | “Single intravenous infusion of anti-FLT3 CAR-T cells” NCT05023707 ↗ |
| Target | FLT3 | “anti-FLT3 CAR T-cells targeting FLT3” NCT05023707 ↗ |